Loading...
In studies that have compared unfractionated heparin (UFH) to various low-molecular weight heparins (LMWHs) for the treatment of patients with non-ST-segment elevation acute coronary syndromes, enoxaparin has been the most effective. In this prospective, randomized, open-label Greek trial, the authors conducted a rare head-to-head comparison of two LMWHs in this population.
A total of 438 patients with chest pain and electrocardiographic changes consistent with ischemia (excluding persistent ST-segment elevation) or left bundle branch block were randomized to receive enoxaparin (100 IU/kg, equivalent to 1 mg/kg, twice daily) or tinzaparin (175 IU/kg, once daily) for up to 7 days. Patients also received aspirin, beta-blockers, and nitroglycer…